Medtronic has agreed to acquire Scientia Vascular in a $550m deal positioned to advance the company’s international presence in the neurovascular guidewire market.
Under the agreement, which holds the potential for undisclosed earn-out and milestone payments post-acquisition, Medtronic will inherit the Utah-based company’s portfolio of access microcatheters and micro guidewires.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Scientia’s products are used in navigating cerebral vasculature associated with the treatment of various neurovascular conditions. Medtronic anticipates that the products will enable “faster and more reliable” access during treatment procedures for conditions such as acute ischemic stroke.
Linnea Burman, senior vice president and president of Medtronic’s neurovascular business, commented: “This acquisition positions Medtronic with a full suite of products. It builds a strong foundation for Medtronic and supports procedures across both haemorrhagic and acute ischemic stroke.”
Scientia’s CEO, Rick Randall, stated that its acquisition by Medtronic would allow the company to take its engineering “into disease states globally”.
GlobalData analysis reveals that the global interventional neuroradiology market, which includes neurovascular products such as micro guidewires, is growing at a CAGR of 8.6% and projected to reach a valuation of around $9.8bn in 2035, up from $4.3bn in 2025.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to Dr Andrew S Thompson, director of therapy research and analysis in medical devices for GlobalData, Medtronic has around $849m in revenue in this category, behind market leader Stryker with $1.3bn, while Scientia is expected to add around $45m within the neuro micro guidewire market segment.
Thompson said: “Scientia only has a significant presence in the US market. Medtronic has a global presence in the neuro micro guidewire space, but with revenue of only $11m.
“Therefore, this acquisition adds product coverage to Medtronic’s portfolio, but importantly, Medtronic will be a good position to leverage its global presence to significantly grow the Scientia franchise as a global player in the neuro guidewire market, with the potential to achieve sales of $80m-$100m if it can replicate Scientia’s share of the US market on the global stage.”
Medtronic expects the acquisition of Scientia to close in the first half of the company’s fiscal year 2027 (FY27). Should the transaction go ahead, it will mark the second big acquisition of the year for the Ireland-headquartered medtech giant. In February, Medtronic announced plans to exercise its option to acquire coronary artery disease (CAD) specialist CathWorks for $585m.
